197 related articles for article (PubMed ID: 199059)
1. Antibodies to Epstein-Barr virus capsid antigen and early antigen in nasopharyngeal carcinoma and comparison groups.
Lin TM; Yang CS; Chiou JF; Tu SM; Chen TY; Tu YC; Lin PJ; Kawamura A; Hirayama T
Am J Epidemiol; 1977 Oct; 106(4):336-9. PubMed ID: 199059
[TBL] [Abstract][Full Text] [Related]
2. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
[TBL] [Abstract][Full Text] [Related]
3. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
[TBL] [Abstract][Full Text] [Related]
4. IgG and IgA antibodies to Epstein-Barr virus in nasopharyngeal carcinoma patients.
Gong SH; Lynn TC; Yang CS
Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1978 Mar; 11(1):8-15. PubMed ID: 211015
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of IgA specific antibodies to Epstein-Barr virus capsid and early antigens in nasopharyngeal carcinoma.
Puthavathana P; Kositanont U; Chongkolwatana C; Metheetrairut C; Chantarakul N; Nuntarakchaikul S; Wasi C
Asian Pac J Allergy Immunol; 1993 Jun; 11(1):39-43. PubMed ID: 8216557
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
[TBL] [Abstract][Full Text] [Related]
7. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
[TBL] [Abstract][Full Text] [Related]
8. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
9. Titers of Epstein-Barr virus-related antibodies in nasopharyngeal carcinoma in Japan.
Tamada A; Makimoto K; Yamabe H; Imai J; Hinuma Y; Oyagi A; Araki T
Cancer; 1984 Feb; 53(3):430-40. PubMed ID: 6318948
[TBL] [Abstract][Full Text] [Related]
10. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I
Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597
[TBL] [Abstract][Full Text] [Related]
11. Detection of Epstein-Barr virus antigens and antibodies by peroxidase-labeled specific immunoglobulins.
Kurstak E; de Thé G; van den Hurk J; Charpentier G; Kurstak C; Tijssen P; Morisset R
J Med Virol; 1978; 2(3):189-200. PubMed ID: 212523
[TBL] [Abstract][Full Text] [Related]
12. Increased incidence of IgA antibodies to the Epstein-Barr virus-associated viral capsid antigen and early antigens in patients with chronic lymphocytic leukemia.
Dölken G; Bross KJ; Hecht T; Brugger W; Löhr GW; Hirsch FW
Int J Cancer; 1986 Jul; 38(1):55-9. PubMed ID: 3013785
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.
Henle G; Henle W
Int J Cancer; 1976 Jan; 17(1):1-7. PubMed ID: 175020
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
[TBL] [Abstract][Full Text] [Related]
15. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antibodies to Epstein-Barr virus in Italian patients with nasopharyngeal carcinoma.
Cevenini R; Donati M; Caliceti U; Moroni A; Tamba I; Rumpianesi F
J Infect; 1986 Mar; 12(2):127-31. PubMed ID: 3009628
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma.
Wong MM; Lye MS; Cheng HM; Sam CK
Asian Pac J Allergy Immunol; 2005 Mar; 23(1):65-7. PubMed ID: 15997877
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
[TBL] [Abstract][Full Text] [Related]
19. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies on immunity to EBV-associated antigens in NPC patients in North America, Tunisia, France and Hong Kong.
Levine PH; Wallen WC; Ablashi DV; Granlund DJ; Connelly R
Int J Cancer; 1977 Sep; 20(3):332-8. PubMed ID: 198381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
